FDA Approves ITonies, Inc.'s Over-The-Counter Nausea Relief Drug Emesyl


Follow this company

Companies Mentioned

PK:ITNS / OTC:BB:CTSO / OTC:BB:ULUR
06/03/2014 [ACCESSWIRE]

ITonis, Inc. (OTCPINK: ITNS) saw very strong share volume on June 3rd with 47,943,425 shares exchanging hands.

This heavy volume comes after ITonis announced that the U.S. Food & Drug Administration (FDA) has published final approval of the Company's National Drug Code (NDC) number (59067-001) for its Emesyl(r) over-the-counter homeopathic product for nausea relief.

The Company will market Emesyl(r) to national retailers, including drugstore retailers, department stores, cruiselines, and other strategic retail sectors upon receiving its first production batch from Oasis. Plans are in place to aggressively market Emesyl(r) for a significant share of the worldwide over-the-counter pharmaceutical market revenues.

"Reaching these significant NDC and trademark milestones required a lot of hard work and patience. We have wasted no time in prompting our manufacturer to finalize all steps for the first production run of Emesyl(r), bringing us one step closer to market," said Dr. Charles H. Hensley, the inventor of Emesyl(r) and the Zicam(r) Cold Remedy.

ITNS closed the day at $.0129, 29% higher than its previous close of $.01.

PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

http://www.pennypickalerts.com

 

Cytosorbents Corp. Sees Share Volume Remain Strong

Cytosorbents Corp. (OTCQB: CTSO) saw its share volume remain strong on June 3rd with 1,310,770 shares exchanging hands, right on par with its three month daily average volume of 1,454,730 shares.

Cytosorbents Corp. has been riding the coattails of its first quarter financial results for 2014. 

Q1 2014 Financial Highlights:

- Record total revenue for the first quarter of 2014 of approximately $1.1M, driven by increases in both product and grant income

- Achieved record quarterly CytoSorb(r) sales of $569K. This represents a sequential 81% increase from the prior quarter product sales of $314K, and a 223% increase over product sales of $176K in Q1 2013

- Product gross margins for Q1 2014 were in excess of 60%

- Grant income increased 152% to $491K during Q1 2014, compared to $195K in Q1 2013

- Successfully raised $10.2M in a March 2014 financing led by Brean Capital, strengthening the balance sheet with $9.5M cash, net of fees and expenses, and providing the company with significant growth capital. As of March 31, 2014, cash and short-term investments were approximately $11.2M

- Received $458K in non-dilutive funding from the New Jersey Technology Business Tax Certificate Transfer Program

CTSO closed the day at $.2485.

PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

http://www.pennypickalerts.com

 

ULURU, Inc. Announces Shipments Of Altrazeal For International Markets

ULURU Inc. (OTCQB: ULUR) saw its share volume surge on June 3rd with 210,006 shares exchanging hands, three times higher than its three month daily average volume of 67,788 shares.

Just last week, ULURU Inc. announced it has completed the further shipments of Altrazeal(r) for the Italian, Spanish and Portuguese markets.

Commenting on these shipments, Helmut Kerschbaumer, Managing Director of Altrazeal GmbH, stated, "This is a significant milestone in the rollout of Altrazeal(r) onto the European market. Coming right behind a highly successful participation at the European Wound Management Association Annual Meeting in Madrid, this is ideal timing to expand the commercial launch of Altrazeal(r) in these important European markets. Extensive clinical data has been generated, and key opinion leader support established during the pre-launch phase. The response of the Spanish wound care professionals to Altrazeal(r) in Madrid was extremely positive. Our partners are well positioned to establish Altrazeal(r) as a leading product in these markets."

Altrazeal(r) is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal(r) competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal(r) has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.

ULUR closed the day at $1.56, 7.59% higher than its previous close of $1.45.

PennyPickAlerts.com is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

http://www.pennypickalerts.com

ABOUT US:

Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.

Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.pennypickalerts.com

Disclosure:

Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

COMMENTS

Leave a comment...
 * 

Your Name
 *